Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study-Reference-Cited by-同舟云学术

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study

Published:2017-09 Issue: Volume:82 Page:230-236
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pivot X.^ORCID,Spano J.P.,Espie M.,Cottu P.,Jouannaud C.,Pottier V.,Moreau L.,Extra J.M.,Lortholary A.,Rivera P.,Spaeth D.,Attar-Rabia H.,Benkanoun C.,Dima-Martinez L.,Esposito N.,Gligorov J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference13 articles.

1. Trastuzumab in the treatment of breast cancer;Hortobagyi;N Engl J Med,2005

2. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

5. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review;Frontiers in Pharmacology;2024-08-19

2. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design;Advanced Drug Delivery Reviews;2024-06

3. Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC;Journal of Thoracic Oncology;2024-05

4. Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis – initial results from the observational SISTER study;Therapeutic Advances in Neurological Disorders;2024-01

5. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer;International Journal of Breast Cancer;2024-01